References in periodicals archive ?
Under the terms of the deal, which was carried out via Celsion's fully-owned unit CLSN Laboratories Inc, the buyer paid USD3m in cash and issued USD8.5m worth of stock to EGEN at closing.
Under the deal, CLSN Laboratories, a subsidiary of Celsion, has acquired all assets and assumed certain of EGEN's specified liabilities.
10 June 2011 - US Celsion Corporation (NASDAQ: CLSN) said on Wednesday that after reviewing safety data from its recently completed Phase I portion of the DIGNITY Phase I/II study of ThermoDox and hyperthermia in recurrent chest wall (RCW) breast cancer, an independent Drug Safety Monitoring Board (DSMB) has recommended advancing from Phase I to Phase II at 50 mg/m2 of ThermoDox.
12 November 2010 - US-based oncology drug development company Celsion Corporation (NASDAQ: CLSN) announced yesterday that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the application for Orphan Drug designation for ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.
24 August 2010 - US-based oncology company Celsion Corporation (NASDAQ: CLSN) today announced that the US Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation (RFA), as a Fast Track Development Programme.
2 August 2010 - US biotechnology drug development company Celsion Corporation (NASDAQ: CLSN) said today it has named Robert Hooper board member.
Acronyms browser ?
Full browser ?